Dr. Eton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
34 Larchwood Drive
Cambridge, MA 02138Phone+1 617-955-0100- Is this information wrong?
Summary
- Practicing academic/community oncologist. Eighteen years in academic oncology then three years in formal Phase 1 drug development. Now twelve years bringing all that to major community hospitals in Boston and then Hartford.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1986 - 1990
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1983 - 1986
- New York University School of MedicineClass of 1983
- Harvard UniversityAB, Biochemistry, with Honors, 1974 - 1978
Certifications & Licensure
- CO State Medical License 2023 - 2025
- TX State Medical License 1985 - 2025
- MA State Medical License 2007 - 2025
- NY State Medical License 1986 - 2025
- KY State Medical License 2024 - 2024
- CT State Medical License 2017 - 2023
- FL State Medical License 2003 - 2008
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patients’ Choice Awards
- Top Doctor in Massachusetts
- Compassionate Doctor Award - National
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsInterplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.Vikas, P., Bakouny, Z., Labaki, C., Grover, P., Awosika, J., Gulati, S., Hsu, C., Alimohamed, S., Bashir, B., Berg, S., Bilen, M., Bowles, D., Castellano, C., Desai, A...> ;JAMA Oncology. 2023 Jan 1
- 24 citationsAdaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).Michael A Postow, Debra A Goldman, Alexander N Shoushtari, Allison Betof Warner, Margaret K Callahan, Parisa Momtaz, James W Smithy, Ellesa Naito, Marina K Cugliari, V...> ;Journal of Clinical Oncology. 2022 Apr 1
- 1 citationsCombining Panitumumab With Anti-PD-1 Antibody in Cutaneous Squamous Cell Carcinoma of the Head and Neck After Inadequate Response to Anti-PD-1 Antibody Alone.Emily Hsu, Omar Eton, Akshay V Patel, Richard W. Cartun, Jonathan Earle, Laila Mnayer, Jennifer Kotowitz, Peter Paul Yu> ;Journal of Drugs in Dermatology. 2021 Aug 1
- Join now to see all
Journal Articles
- Melanoma brain metastasis: overview of current management and emerging targeted therapiesFonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET, Expert Rev Neurother, 1/1/2012
- Autologous tumor-derived heat-shock protein peptide complex-96 in patients with metastatic melanomaEton O, Savary CA, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Plager C, Bedikian AY, Reitsma D, Lee JE, J Transl Med, 1/1/2010
- Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamicsMacarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton ..., Molecular Cancer Therapeutics, 1/1/2010
- Join now to see all
Abstracts/Posters
- Phase I Evaluation of MLN8237, a Novel Aurora A Kinase InhibitorDees EC, Infante J, Burris H, O’Neil B, Murphy P, Eton O, Lee Y, Pappas J, Ecsedy JA, Cohen RB, Chemotherapy Foundation Symposium XXVI, 11/4/2008
- Phase I and Pharmacokinetic Study of MLN8054, a Selective Inhibitor of Aurora A KinaseDees EC, Infante JR, Cohen RB, O’Neil BH, Burris H, von Mehren M, Gray G, Galvin K, Manfredi M, Eton O, EORTC-NCI-AACR 2008 Conference, 10/21/2008
- Phase I Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of MLN8237, a Selective Aurora A Kinase Inhibitor, in the United StatesInfante J, Dees EC, Cohen RB, Burris H, O’Neil B, Murphy P, Lee Y, Pappas J, Ecsedy JA, Eton O, EORTC-NCI-AACR 2008 Conference, 10/21/2008
- Join now to see all
Press Mentions
- CT Ranks Second for Skin Cancer Rates: ReportJune 7th, 2018
Committees
- ASCO, Clinical Practice Committee 2012 - Present
- ASCO, State Affiliates Committee 2012 - Present
- Treasurer then President, Massachusetts Society of Clinical Oncologists 2009 - Present
Professional Memberships
- Member
Other Languages
- French, Spanish
Hospital Affiliations
- Cape Cod HospitalHyannis, Massachusetts
Industry Relationships
- Consultant, MerckSpeakers' Bureau, anti-PD1Disclosure: Consultant fee2014 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: